Renalytix Appoints Ann Berman to its Board of Directors
28 Luglio 2021 - 1:00PM
Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the
appointment of Ann E. Berman to its board of directors. She will
chair the board’s audit committee and serve as member of the
nomination committee.
Ms. Berman currently serves on the board of directors and as a
member of the audit committee of Loews Corporation (NYSE: L), a
$14.5 billion market capitalization company with subsidiaries that
include CNA Financial. In addition, Ms. Berman is a member of the
board of trustees of Beth Israel Deaconess Medical Center, where
she is the chair of the compliance and risk committees and
Immuneering Corporation where she chairs the audit committee.
“We are delighted to have a professional of Ann’s capabilities
on board as Renalytix enters into a substantial growth phase,” said
Christopher Mills, interim chairman, Renalytix. “Her leadership and
operational experience will be invaluable to helping us drive
shareholder value.”
Ms. Berman commented, “Renalytix is doing important and exciting
work in improving the care and treatment of kidney disease. I am
very pleased to contribute my expertise to advancing the company
and supporting its goals.”
Preceding her retirement in 2009, Ms. Berman served as chief
financial officer of Harvard University. During her tenure at
Harvard, Ms. Berman was responsible for financial strategy, policy
and planning, financial reporting and operations, treasury and risk
management, and various audit functions. As part of her role, she
served on the board of Harvard Management Company, the investment
management firm for Harvard University’s endowment. Before joining
Harvard University, from 1978 to 1985, Ms. Berman was a partner
with Richard A. Eisner & Co., an accounting firm. She began her
career in finance at Price Waterhouse & Co.
Ms. Berman is a certified public accountant who is qualified as
a financial expert for audit committee leadership, with extensive
experience overseeing audit-related matters, enterprise risk
management, internal audit, cybersecurity, and compliance. Ms.
Berman earned a B.A. in French language and literature at Cornell
University, Phi Beta Kappa, and an M.B.A. with a concentration in
accounting from the University of Pennsylvania’s Wharton School of
Business.
About RenalytixRenalytix (LSE: RENX) (NASDAQ:
RNLX) is a developer of artificial intelligence-enabled clinical in
vitro diagnostic solutions for kidney disease, one of the most
common and costly chronic medical conditions globally. The
Company’s lead product is KidneyIntelX, which has been granted
Breakthrough Designation by the U.S. Food and Drug Administration
and which is being designed to help make significant improvements
in kidney disease prognosis, transplant management, clinical care,
patient stratification for drug clinical trials, and drug target
discovery (visit www.kidneyintelx.com). For more information, visit
www.renalytix.com.
Forward Looking StatementsStatements contained
in this press release regarding matters that are not historical
facts are “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995, as amended.
Examples of these forward-looking statements include statements
concerning: the potential for KidneyIntelX to receive regulatory
approval from the FDA, the commercial prospects of KidneyIntelX, if
approved, including whether KidneyIntelX will be successfully
distributed and marketed, our expectations regarding reimbursement
decisions, our plans for expansion of our business and the ability
of KidneyIntelX to curtail costs of chronic and end-stage kidney
disease, optimize care delivery and improve patient outcomes. Words
such as “anticipates,” “believes,” “estimates,” “expects,”
“intends,” “plans,” “seeks,” and similar expressions are intended
to identify forward-looking statements. We may not actually achieve
the plans and objectives disclosed in the forward-looking
statements, and you should not place undue reliance on our
forward-looking statements. Any forward-looking statements are
based on management's current views and assumptions and involve
risks and uncertainties that could cause actual results,
performance or events to differ materially from those expressed or
implied in such statements. These risks and uncertainties include,
among others: that KidneyIntelX is based on novel artificial
intelligence technologies that are rapidly evolving and potential
acceptance, utility and clinical practice remains uncertain; we
have only recently commercially launched KidneyIntelX; and risks
relating to the impact on our business of the COVID-19 pandemic or
similar public health crises. These and other risks are described
more fully in our filings with the Securities and Exchange
Commission (SEC), including the “Risk Factors” section of our
annual report on Form 20-F filed with the SEC on October 28, 2020,
and other filings we make with the SEC from time to time. All
information in this press release is as of the date of the release,
and we undertake no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events, or otherwise, except as required by law.
Media Contacts:United States:Jennifer
MoritzZer0 to 5ive for Renalytix(917) 748-4006jmoritz@0to5.com
Outside of the United States:Walbrook PR
Limited Paul McManus
/ Lianne CawthorneTel: 020 7933 8780 or
renalytix@walbrookpr.comMob: 07980 541 893 / 07584 391
303
AIM Rule regulatory disclosures
In accordance with Schedule 2(g) of the AIM Rules, Ann Elyse
Berman (aged 69) holds or has held in the past 5 years the
following directorships and partnerships:
Current |
Past 5 years |
Loews Corporation |
Cantel Medical Corporation |
Beth Israel Deaconess Medical
Center |
Eaton Vance Corporation |
Immuneering Corporation |
|
Save for the disclosures above, there are no further disclosures
to be made in accordance with AIM Rule 17 and Schedule 2(g) of the
AIM Rules.
Grafico Azioni Loews (NYSE:L)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Loews (NYSE:L)
Storico
Da Mag 2023 a Mag 2024